The Antibacterial Resistance Leadership Group conducts clinical research to combat the growing public health threat of antibiotic-resistant bacteria, which cause 2 million infections and more than 20,000 deaths in the U.S., according to a release.
A recent series of articles published in the journal Clinical Infectious Disease examines the progress made by the ARLG.
Here are three things to know about ARLG.
1. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched the ARLG in June 2013 with $2 million in funding.
2. The group's research centers on four critical areas: gram-negative bacteria like Escherichia coli, Klebsiella pneumoniae and carbapenem-resistant Enterobacteriaceae; gram-positive bacteria like methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci; antimicrobial stewardship; and advancing the field of infectious disease diagnostics.
3. Since its inception, the ARLG has conducted more than 30 clinical studies and reviewed more than 70 study proposals in these key areas of focus.
More articles on infection control:
Flu activity declines, but hospitalizations and pediatric deaths see uptick
4 notes on infection control coordinator pay by experience level
Physician-scheduled appointments linked to higher flu shot rate, study shows